KRAS and neoplasm: In patients with metastatic colorectal cancer (CRC), KRAS mutational analysis is used to determine the status of the KRAS gene (wild type or mutant) in tumor specimens.  Persons whose tumors are wild type may respond to therapies cetuximab (Erbitux) or panitumumab (Vectibix).